such cell contained more than a single X-chromosome, making fusion mechanisms unlikely. However, in daughter epithelial cells such as those contained in buccal swabs, chromosomes could be lost.
The incidence of donor-derived epithelial cells in the oral mucosa (1.8%) is much greater than the incidence of chimeric events described in the colon crypts in patients after HCT (0.18%) identified with the same methodology. 3 Although no direct comparison can be carried out, it might be that the higher cell turnover in oral mucosa (2.5 days) as compared to colon tissue (5 days) plays a role in the extent of the epithelial chimerism. The number of donor-derived epithelial buccal cells found here (0.2-7.3%) correspond to that in the study of Tran et al 4 in which no exclusion of lymphocyte contamination was carried out. Probably, the low numbers of hematopoietic cells in the buccal smears of the transplanted patients (up to 1%) combined with the relative high incidence of donorderived buccal cells (up to 7.3%) does not dramatically influences the measurement of the donor-derived epithelial cell numbers. Nevertheless, our rigorous analysis demonstrates definitely that individual buccal epithelial cells after HCT are donor derived.
In conclusion, our examination of single cells demonstrates that peripheral blood HCT in humans results not only in replacement of the lymphohematopoietic system but also in the generation of individual donor-derived epithelial cells. Although not irrefutable, our results suggest that fusion is not the underlying mechanism. Whether donor-derived epithelial cells are an incidental by-product of transplantation without ancillary biological significance or whether they hold any clinical, pathological 8 and/or therapeutical relevance remains to be answered by examination of a great number of transplanted patients. Considering the ease and noninvasive access of buccal cells, we suggest that chimerism studies as the ones described here should be routinely performed in sex-mismatched transplanted females. 1 Recently, using DNA microarray analysis it has been shown that ZAP-70 is highly expressed in CLL patients with unmutated status, while the mutated group usually has low ZAP-70 expression.
T-cell ZAP
2 Subsequent studies with larger numbers of CLL patients demonstrated that ZAP-70 expression in CLL cells can predict the mutational status, and that ZAP-70 levels also correlate with disease progression, and overall survival. 3, 4 ZAP-70 is a member of the syk family protein tyrosine kinases (PTKs), which plays a critical role in T-cell antigen receptor (TCR) signaling and T-cell development.
5 ZAP-70 is normally expressed in T lymphocytes and NK cells but is not present in normal B lymphocytes. 5 The detection of ZAP-70 expression in CLL raises many questions concerning its role in the pathogenesis of the disease. In this respect, it has been shown that CLL cells expressing high levels of ZAP-70 are associated with enhanced signal transduction via the B-cell receptor (BCR) complex, when compared to CLL cells with low expression of ZAP-70. 6 In this study, we present data on T-cell ZAP-70 expression in CLL. Our results indicate that overexpression of T-cell ZAP-70 correlates with the ZAP-70 levels in the leukemic CLL cells and is associated with more advanced disease and a progressive clinical course.
Peripheral blood samples were collected from 35 patients with CLL (Table 1) and from eight normal volunteers. Blood samples were obtained with written informed consent. Cell staining and flow-cytometric analysis of ZAP-70 expression was performed according to the recently described method. To the best of our best knowledge, overexpression of T-cell ZAP-70 has not been reported in other diseases; however, downregulation of ZAP-70 has been recorded in some malignancies. 7 In this respect, it is possible that ZAP-70 expression in T cells can be modulated by different cytokines such as IL-2. 8 In the light of the results of this study, we In two of the 35 patients relevant clinical data were not available for the follow-up analysis. speculate that high ZAP-70 expression in the peripheral blood CLL T-cells (particularly patients with X20% positive ZAP-70 CLL cells and those with advanced stages and progressive disease) may be indicative of a state of T-cell activation. In this respect, circulating T-cells in CLL are considered as partially activated 9 and their activation status appears to be dependent on disease stage and clinical progression. 9 The positive correlation between ZAP-70 expression in CLL cells and in T-cells from the same patients may also represent a dual activation loop involving T-cell/CLL cell interaction and intercellular crosstalk.
In this regard, the recent results of a gene microarray study of follicular B-cell lymphoma, showing the central role of the microenvironment in the pathogenesis of this disorder, are of great interest. 10 In the latter study, it was evident that the geneexpressing signatures of T-cells, macrophages and dendritic cells, but not those of B-cell lymphoma cells, serve as a prognostic index of survival. 10 The above data suggest a causative link between T-and B-lymphoma cells, while our study on CLL provides additional clinical support for the concept and suggests that B-and T-cell interaction may have an impact on the clinical outcome. Future more extensive studies with larger numbers of patients may well shed further light on these aspects of CLL. Some observations support the hypothesis that hypomethylation is associated with increased DNA recombination, chromosomal aberrations, mitotic dysfunction and translocations, 1,2 and an increased tumor formation rate. 3, 4 The MLL gene is often disrupted by chromosomal translocation in infant ALL and AML, in de novo AML, and in therapy-related myeloid leukemia (t-ML) following topoisomerase II inhibitors, such as etoposide. MLL seems to be particularly prone to cleavage 
